首頁
Evox Therapeutics

7月 2026Evox Therapeutics的市場佔有率分析

Rewriting the narrative of neurodegenerative disease Next-generation gene editing addressing the root cause of neurodegeneration Our Mission We are committed to expanding the reach of genetic medicine into the brain and transforming the treatment landscape for severe neurodegenerative diseases. Evox’s exosome-based therapies are designed to deliver safer, more effective and commercially scalable treatments, drawing on ... Read more

健康 > 生物技術和製藥

域名evoxtherapeutics.com

成立年份2016

僱員51 - 200

年度營收$10M - $15M

Evox Therapeutics

Evox Therapeutics（包含公司地區）

evoxtherapeutics.com

查看更多網站流量與參與度資訊

Evox Therapeutics截至 7月 2026 的總收入為 10M - 15M

Evox Therapeutics 熱門網域產生的總收入

Evox Therapeutics 熱門網域 3 年內的總收入

Evox Therapeutics 熱門網域的總收入

evoxtherapeutics.com10M - 15M

透過銷售情報查看更多內容

Evox Therapeutics的熱門網域總造訪量

了解Evox Therapeutics市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

evoxtherapeutics.com5.5K

透過銷售情報查看更多內容

Evox Therapeutics的熱門網域平均造訪時長

分析Evox Therapeutics參與度指標。

過去 3 個月平均造訪時長

子公司細目

evoxtherapeutics.com00:00:03

透過銷售情報查看更多內容

Evox Therapeutics的熱門網域平均頁面瀏覽量

了解Evox Therapeutics如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

evoxtherapeutics.com1.52

透過銷售情報查看更多內容

Evox Therapeutics按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術Evox Therapeutics

这些是Evox Therapeutics顶级域名使用的行业网站技术

付款與貨幣 (5)

Cart Functionality

小工具 (5)

Twemoji

內容管理系統 (3)

WordPress

轉換與分析 (3)

Google Analytics

更多技術

8

檢視所有

新聞與訊號來自Evox Therapeutics

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞eXmoor Pharma Concepts Ltd partnered with Evox Therapeutics Ltd. on Jul 21st '26.Bristol, UK - 21 July 2026: eXmoor Pharma ('eXmoor'), the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Evox Therapeutics ('Evox') have completed a technology transfer programme for Evox's exosome-enabled gene editing technology and specifically its MSH3-targeted programme for the treatment of Huntington's disease.

新聞Evox Therapeutics Ltd partnered with Rett Syndrome Research Trust on Feb 26th '26.OXFORD, United Kingdom, February 26, 2026 - Evox Therapeutics Ltd ("Evox" or the "Company"), a biotechnology company developing innovative therapies for genetically driven neurodegenerative diseases using a next-generation gene editing modality, today announced it is initiating a collaboration with the Rett Syndrome Research Trust (RSRT) to assess the feasibility of using the Company's ExoEdit(R) exosome-based delivery platform to enable the development of a gene editing treatment for Rett syndrome.

新聞Evox Therapeutics Ltd promoted Per Lundin to Chief Executive Officer on Apr 29th '24.Oxford, U.K. April 29, 2024 - Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, announces that Dr. Per Lundin, Co-Founder and Chief Business Officer, has been appointed as Chief Executive Officer (CEO) of the Company and will be appointed to its Board of Directors.